首页> 外国专利> ANTIBIOTIC WITH MODIFIED SIDE EFFECTS FOR HOSPITALIZED PATIENTS (NEW PROTOCOL, NEW COMPOUND DRUG)

ANTIBIOTIC WITH MODIFIED SIDE EFFECTS FOR HOSPITALIZED PATIENTS (NEW PROTOCOL, NEW COMPOUND DRUG)

机译:用于住院患者的改性副作用的抗生素(新的协议,新复合药物)

摘要

Nephrotoxicity is the most known side effect of gentamicin, antibiotic which is widely used to treat Gram-negative infections. Probably reactive oxygen species (ROS) are responsible for gentamicin induced nephrotoxicity. In addition, RAS plays an important role in the pathogenesis of renal injury, and nephrotoxicity. Hypo magnesium is other complication of gentamicin. Therefore, considering the antioxidant effects of losartan and MgSO4 in recent studies, we made new generation of drug. This drug contains gentamicin as antibiotic plus losartan and MgSO4 as adjuvant to reduce gentamicin nephrotoxicity especially in hypertensive patients. On the other-hand we suggest prescription of gentamicin with MgSO4 and lower dosage of losartan for maximum nephroprotective effects in hospitalized patients.
机译:肾毒性是庆大霉素,抗生素的最着名的副作用,广泛用于治疗革兰氏阴性感染。可能是活性氧(ROS)负责庆大霉素诱导的肾毒性。此外,RAS在肾损伤和肾毒性的发病机制中起着重要作用。 Hypo镁是庆大霉素的其他复杂性。因此,考虑到氯沙坦和MgSO4在最近的研究中,我们制作了新一代药物。这种药物含有庆大霉素作为抗生素加尔沙坦和MgSO4,作为佐剂,以减少庆大霉素肾毒性,特别是在高血压患者中。另一方面,我们建议庆大霉素的处方于MgSO4和氯沙坦的较低剂量,用于在住院患者中最大的肾脏保护作用。

著录项

  • 公开/公告号WO2021084562A2

    专利类型

  • 公开/公告日2021-05-06

    原文格式PDF

  • 申请/专利权人 KOURKINEJAD GHARAEI FATEMEH;

    申请/专利号WO2019IR50032

  • 发明设计人 KOURKINEJAD GHARAEI FATEMEH;

    申请日2019-11-12

  • 分类号

  • 国家 IR

  • 入库时间 2022-08-24 18:36:54

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号